Outset Medical (NASDAQ:OM) CFO Renee Gaeta Sells 17,672 Shares

by · The Markets Daily

Outset Medical, Inc. (NASDAQ:OM – Get Free Report) CFO Renee Gaeta sold 17,672 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68. Following the completion of the transaction, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at approximately $561,939.82. The trade was a 13.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Price Performance

Shares of Outset Medical stock traded down $0.15 during trading on Friday, hitting $4.58. The stock had a trading volume of 128,565 shares, compared to its average volume of 496,705. The company has a current ratio of 6.29, a quick ratio of 4.97 and a debt-to-equity ratio of 0.87. Outset Medical, Inc. has a 12 month low of $3.00 and a 12 month high of $21.98. The firm has a market cap of $84.90 million, a price-to-earnings ratio of -1.10 and a beta of 1.95. The business’s 50-day moving average is $4.24 and its 200 day moving average is $4.17.

Outset Medical (NASDAQ:OM – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.04). Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%.The business had revenue of $27.86 million for the quarter, compared to analysts’ expectations of $28.90 million. As a group, sell-side analysts anticipate that Outset Medical, Inc. will post -3.82 earnings per share for the current year.

Institutional Investors Weigh In On Outset Medical

Institutional investors have recently bought and sold shares of the stock. BML Capital Management LLC raised its holdings in Outset Medical by 250.2% in the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock worth $7,304,000 after purchasing an additional 1,359,021 shares in the last quarter. Alyeska Investment Group L.P. increased its stake in shares of Outset Medical by 10.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after acquiring an additional 150,000 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Outset Medical by 71.8% in the 4th quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock worth $2,078,000 after acquiring an additional 234,082 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Outset Medical by 34.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock valued at $1,886,000 after acquiring an additional 131,381 shares during the period. Finally, Millennium Management LLC boosted its stake in Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after acquiring an additional 262,874 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have recently commented on OM. BTIG Research decreased their price target on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a report on Friday, March 27th. TD Cowen reissued a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Finally, Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.00.

View Our Latest Research Report on OM

About Outset Medical

(Get Free Report)

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.

See Also